Recent studies have highlighted notable progress in cancer treatment approaches. Novel immunotherapy scaffolds and bispecific antibodies show potential for difficult cancers such as glioblastoma and ovarian cancer. Early phase trials of gene therapies for rare cancers demonstrate encouraging functional outcomes. In addition, analysis of molecular and immune biomarkers is refining prognosis and therapeutic targeting, offering a more personalized approach to oncology care.